GlassScriptPhysician profile
Deborah Schulte Long
NPI 1598712713
$1,668.38
in general payments reported to CMS, 2019-2025
23 companies · $634 in 2025
The $634 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.64 · 2022: $347 · 2023: $223 · 2024: $390 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $412.00 | 2021-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $327.43 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Ucb, INC. | $232.17 | 2022-2025 | Cimzia, Bimzelx |
| Dexcom, INC. | $96.17 | 2021-2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $76.09 | 2022-2023 | Injectafer |
| Sanofi-Aventis U.S. LLC | $70.42 | 2024 | |
| Lilly USA, LLC | $53.55 | 2023-2024 | Jardiance, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $46.71 | 2025 | Orencia |
| Bayer Healthcare Pharmaceuticals INC. | $39.05 | 2022-2024 | |
| Janssen Biotech, INC. | $38.41 | 2022-2025 | Tremfya |
| Ibsa Pharma INC. | $37.07 | 2022-2023 | Tirosint, Licart |
| Corcept Therapeutics | $33.45 | 2024 | Korlym |
| Baxter Healthcare | $23.13 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Averitas Pharma INC. | $22.08 | 2025 | Qutenza |
| Organon LLC | $21.35 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $21.27 | 2024 | Cologuard Collection Kit |
| Ani Pharmaceuticals, INC. | $18.89 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $18.22 | 2024 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $17.94 | 2024 | Opsumit, Uptravi |
| Amryt Pharma Holdings LTD | $16.81 | 2023 | Mycapssa |
| Abbott Laboratories | $15.99 | 2025 | Freestyle Libre 3 |
| Invivyd INC | $15.35 | 2025 | Pemgarda |
| Astrazeneca Pharmaceuticals LP | $14.83 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Schulte Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.